Endpoints News 生物医药· Reynald Castaneda·· 16 天前AI 评分48
艾伯维斥资14.7亿美元与Nxera合作开发肠道靶向IBD项目
AbbVie bets up to $1.47B on Nxera's gut-targeting IBD program
AI 导读
艾伯维以1亿美元预付款与Nxera合作,开发EP4受体激动剂项目,潜在里程碑付款高达13.7亿美元。
正文
AbbVie is licensing Nxera Pharma’s EP4 receptor agonist program for $100 million upfront, with up to $1.37 billion at stake in development and commercial milestones.
…
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news